The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma

Mostrar otras versiones (1)

BACKGROUND: Cholangiocarcinoma is an aggressive malignancy with limited therapeutic options. MEK inhibition and antiangiogenic therapies have individually shown modest activity in advanced cholangiocarcinoma, whereas dual inhibition of these pathways has not been previously evaluated. We evaluated t...

Descripción completa

Detalles Bibliográficos
Autores principales: Shroff, Rachna T, Yarchoan, Mark, O'Connor, Ashley, Gallagher, Denise, Zahurak, Marianna L, Rosner, Gary, Ohaji, Chimela, Sartorius-Mergenthaler, Susan, Subbiah, Vivek, Zinner, Ralph, Azad, Nilofer S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2017
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520097/
https://www.ncbi.nlm.nih.gov/pubmed/28441383
http://dx.doi.org/10.1038/bjc.2017.119

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5520097/
https://www.ncbi.nlm.nih.gov/pubmed/28441383
http://dx.doi.org/10.1038/bjc.2017.119

Ejemplares similares